Tactile Systems Technology, Inc. (TCMD) - Stock Analysis
Last updated: Apr 26, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Q4 beat with 21% revenue growth, margin expansion, deleveraging (term loan repaid), and a buyback plus positive clinical data for Flexitouch have produced a sharp breakout (~10% over 21 days, 15% above the 21-day SMA); near-term upside is supported by strong fundamentals and follow-through on payer/volume metrics.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Liquidity ⢠Improving Margins ⢠Rich Valuation TCMD has strong liquidity, low leverage, and solid cash generation with improving margins and returns, but its rich valuation and still-high operating costs temper the overall appeal.
Price Behavior
Key Price Behavior Insights: ⢠Lower highs ⢠Support holding ⢠Resistance capped Support Level: $24.2 to $24.5, then $23.4 Resistance Level: $25.7 to $26.0 TCMD has been range-bound and slightly weaker over the last month, with buyers defending the low-$24s but rallies still stalling near $25.7-$26.0, keeping the short-term setup mixed.
Sentiment & News
Key News Insights: ⢠Analyst support ⢠Price weakness ⢠Earnings ahead TCMD is attracting mixed-but-positive analyst interest as valuation support and a âModerate Buyâ stance are offset by recent price weakness below the 50-day moving average ahead of its May 4 earnings report.
AI Summary
TCMD now looks less like a cheap, fragile medtech and more like a cash-generating growth story with real operating leverage, but with a ~33x P/E the upside depends on sustained low-to-mid teens revenue growth, continued margin expansion, and successful LymphaTech integration rather than valuation rerating.
Description
Tactile Systems Technology, Inc. is a U.S.-based medical device company that produces and markets noninvasive therapies for chronic conditions. Its product portfolio includes pneumatic compression systems for lymphedema and other venous disorders and a portable chest wall oscillation device for managing retained pulmonary secretions. The company was incorporated in 1995 and is headquartered in Minneapolis, Minnesota.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Feb 19 | Feb 26 | TCMD | Tactile Systems Technology, Inc. | Q4 beat with 21% revenue growth, margin expansion, deleveraging (term loan repaid), and a buyback plus positive clinical data for Flexitouch have produced a sharp breakout (~10% over 21 days, 15% above the 21-day SMA); near-term upside is supported by strong fundamentals and follow-through on payer/volume metrics. | Closed | +5.9% |